What is Generate Biomedicines, Inc. 's AOCI?

Generate Biomedicines, Inc. (GENB) reported AOCI of $24K in Q1 2026.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Generate Biomedicines, Inc. GENB AOCI

AOCI at other companies

MYR GroupMYRG

-$9.49M+24.3%

NNN REITNNN

-$4.45M+42.9%

Piper SandlerPIPR

$1.76M+4,188%

RepligenRGEN

-$14.31M+70.1%

Xometry, Inc.XMTR

$4.08M+238%

Mirion TechnologiesMIR

-$62.6M+20.9%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's AOCI?: Generate Biomedicines, Inc. (GENB) reported AOCI of $24K in Q1 2026.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.